Canada Markets closed
  • S&P/TSX

    20,101.38
    -389.63 (-1.90%)
     
  • S&P 500

    3,923.68
    -165.17 (-4.04%)
     
  • DOW

    31,490.07
    -1,164.52 (-3.57%)
     
  • CAD/USD

    0.7766
    +0.0006 (+0.0777%)
     
  • CRUDE OIL

    108.38
    -1.21 (-1.10%)
     
  • BTC-CAD

    37,088.54
    -2,448.60 (-6.19%)
     
  • CMC Crypto 200

    641.18
    -29.49 (-4.40%)
     
  • GOLD FUTURES

    1,814.30
    -1.60 (-0.09%)
     
  • RUSSELL 2000

    1,774.85
    -65.45 (-3.56%)
     
  • 10-Yr Bond

    2.8860
    -0.0820 (-2.76%)
     
  • NASDAQ futures

    11,846.00
    -89.50 (-0.75%)
     
  • VOLATILITY

    30.96
    +4.86 (+18.62%)
     
  • FTSE

    7,438.09
    -80.26 (-1.07%)
     
  • NIKKEI 225

    26,911.20
    0.00 (0.00%)
     
  • CAD/EUR

    0.7411
    -0.0002 (-0.03%)
     

SHAREHOLDER ALERT: Robbins LLP Investigates Generation Bio Co. (GBIO) on Behalf of Shareholders

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

SAN DIEGO, December 29, 2021--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP is investigating Generation Bio Co. (NASDAQ: GBIO) to determine whether certain Generation Bio officers and directors violated the Securities Exchange Act of 1934 and breached fiduciary duties to shareholders. Generation Bio develops gene therapies for the treatment of rare and prevalent diseases.

If you would like more information about our investigation of Generation Bio Co.'s misconduct, click here.

Generation Bio Co. (GBIO) Reports Poor Results for Preclinical Studies for Hemophilia A Program

On December 14, 2021, Generation Bio issued a press release that "provided an update on factor VIII expression from a series of mouse and companion non-human primate (NHP) studies in hemophilia A, as well as an update on the development of its non-viral genetic medicine platform. Generation Bio’s proprietary genetic medicine technology comprises a closed-ended DNA (ceDNA) delivered via a novel, cell-targeted lipid nanoparticle (ctLNP)." The Company disclosed results that showed that in mice, ceDNA generated peak mean human factor VIII expression of 205% of normal at 2.0 mg/kg, and advised that "[a]dditional optimization is needed to translate the improvement in potency and reduction in variability observed in mice to [non-human primates], and to support nomination of a development candidate for the company’s hemophilia A program[.]" On this news, Generation’s stock price fell $7.91 per share to close at $5.99 per share on December 14, 2021.

Generation Bio Co. (GBIO) shareholders have legal options. If you own, or have previously owned, shares of Generation Bio Co., contact us for more information about your rights.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

Contact us to learn more:

Aaron Dumas
(800) 350-6003
adumas@robbinsllp.com
Shareholder Information Form

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Generation Bio Co. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211228005219/en/

Contacts

Aaron Dumas
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting